Hepbest Tablet contains Tenofovir Alafenamide 25 mg, a potent antiretroviral agent used primarily in the treatment of chronic hepatitis B virus (HBV) infection. Tenofovir Alafenamide is a nucleotide reverse transcriptase inhibitor (NRTI) that works by inhibiting the reverse transcriptase enzyme, thereby preventing viral replication and reducing the viral load in infected individuals. Hepbest Tablet is indicated for adult patients with chronic HBV infection with evidence of active viral replication and either elevated liver enzymes or histological evidence of liver damage. Compared to its predecessor Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide offers improved safety with reduced renal and bone toxicity due to its enhanced stability in plasma and targeted delivery to hepatocytes. The recommended dosage is one tablet daily, with or without food, and treatment duration should be determined by the healthcare provider based on virological response and clinical status. Regular monitoring of renal function, liver enzymes, and viral load is advised during therapy. Hepbest Tablet should not be used in patients with known hypersensitivity to Tenofovir Alafenamide or any of its excipients. It is essential to adhere strictly to prescribed regimens to prevent the development of drug resistance.